Federal Policy
Federal legislation, DEA rulemaking, FDA actions, and White House policy on cannabis.
The CMS Innovation Center launched its Substance Access Beneficiary Engagement Incentive on April 1, allowing select Medicare patients to receive up to $500 in physician-supervised, hemp-derived CBD products annually. But an April 20 court date could shut it down before it scales.
The latest version of the cannabis banking bill adds protections for ancillary businesses and state-legal hemp operators. Sponsors say rescheduling momentum gives it the best chance yet.
The rule replaces the delta-9-only standard from the 2018 Farm Bill with a total-THC measurement, effectively banning most intoxicating hemp products at the federal level.
A deep dive into the tax provision that prevents marijuana businesses from deducting ordinary expenses, and the massive financial implications of a move to Schedule III.
A survey of state-level social equity programs reveals a pattern: ambitious promises at launch, followed by bureaucratic delays, underfunding, and capture by well-financed operators.